期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Factors Associated with Thrombolysis Outcome in Ischemic Stroke Patients with Atrial Fibrillation 被引量:14
1
作者 Qiuyun Zhao Xiaobo Li +16 位作者 Wanli Dong Min Ye Yongjun Cao Meijuan Zhang Qiantao Cheng Junshan Zhou Guofang Chen Ming Yu Shanshan Hong Xiue Wei Bei Wang Guiyun Cui Peng Zhang Hong Ding Rongzhen Xu Yan Chen Yun Xu 《Neuroscience Bulletin》 SCIE CAS CSCD 2016年第2期145-152,共8页
The outcome of early intravenous thrombolysis for ischemic stroke in patients with atrial fibrillation(AF)is worse than that without thrombosis. How to increase the efficacy of intravenous thrombolysis for AF-relate... The outcome of early intravenous thrombolysis for ischemic stroke in patients with atrial fibrillation(AF)is worse than that without thrombosis. How to increase the efficacy of intravenous thrombolysis for AF-related ischemic stroke remains largely unknown. In this study, we investigated factors that influence the effect of intravenous thrombolysis in these patients. Our results showed that thrombolysis was independently associated with a favorable outcome(P / 0.001) and did not influence the mortality of AF-related ischemic stroke, although it increased the risk of hemorrhage within 24 h after treatment. Risk factors for a poor outcome at admission were:heart failure(P = 0.045); high systolic pressure(P = 0.039); high blood glucose(P = 0.030); and a high National Institutes of Health Stroke Scale(NIHSS) score(P / 0.001). Moreover, high systolic pressure at admission(P = 0.007), high blood glucose(P = 0.027), and a high NIHSS score(P / 0.001) were independent risk factors for mortality at 3 months. Besides thrombolysis, a high NIHSS score(P = 0.006) and warfarin taken within 48 h before stroke onset(P = 0.032) were also independent risk factors for symptomatic hemorrhage within 24 h after treatment. Ischemic stroke patients with AF benefited from intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 h after stroke. 展开更多
关键词 Ischemic stroke Atrial fibrillation Intravenous recombinant tissue plasminogen activator Intravenous thrombolysis Favorable outcome Risk factors
原文传递
Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator 被引量:19
2
作者 HUANG Yin-hui ZHUO Shi-tu +5 位作者 CHEN Ya-fang LI Ming-mei LIN You-yu YANG Mei-li CHEN Zhen-jie CAI Ruo-wei 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第24期4685-4690,共6页
Background Thrombolysis with recombinant tissue plasminogen activator (rt-PA) has gained international recognition, clinical outcomes following this thrombolytic therapy varied from patient to patient. Factors affec... Background Thrombolysis with recombinant tissue plasminogen activator (rt-PA) has gained international recognition, clinical outcomes following this thrombolytic therapy varied from patient to patient. Factors affecting clinical outcomes have not been well understood yet, so this retrospective case-control study aimed to investigate factors that may influence clinical outcomes of acute ischemic stroke treated with intravenous rt-PA. Methods One hundred and one patients with acute ischemic stroke who received intravenous rt-PA thrombolysis within 4.5 hours from disease onset were included. Patients were divided into good or poor outcome group according to modified Rankin Scale (mRS) score, good outcome group: mRS score of 0-1; poor outcome group: mRS of 2-6. Stroke characteristics were compared between the two groups. Factors for stroke outcomes were analyzed via univariate analysis and Logistic regression. Results Of the 101 patients studied, patients in good outcome group (n=55) were significantly younger than patients in poor outcome group (n=46, (62.82±14.25) vs. (68.81±9.85) years, P=0.029). Good outcome group had fewer patients with diabetic history (9.09% vs. 28.26%, P=0.012), fewer patients with leukoaraiosis (7.27% vs. 28.26%, P=-0.005) and presented with lower blood glucose level ((5.72±1.76) vs. (6.72±1.32) mmol/L, P=0.012), lower systolic blood pressure level ((135.45±19.36) vs. (148.78±19.39) mmHg, P=0.003), lower baseline NIHSS score (12.02±5.26 vs. 15.78±4.98, P=0.002) and shorter onset-to-treatment time (OTT) ((2.38±1.21) vs. (2.57±1.03) hours, P=0.044) than poor outcome group. Logistic regression analysis showed that absence of diabetic history (odds ratio (OR) 0.968 (95% CI 0.941-0.996)), absence of leukoaraiosis (OR 0.835 (95% C/0.712-0.980)), lower baseline NIHSS score (OR 0.885 (95% Cl 0.793- 0.989)), lower pre-thrombolysis systolic blood pressure (OR 0.962 (95% CI 0.929-0.997)), and lower blood glucose level (OR 0.699 (95% Cl 0.491-0.994)) before thrombolysis were significantly associated with better outcome. Conclusion Patients with no history of diabetes, no leukoaraiosis, low blood glucose level, low systolic blood pressure level and low baseline NIHSS score before thrombolvsis have a better outcome. 展开更多
关键词 recombinant tissue plasminogen activator introvenous thrombolysis acute ischemic stroke outcome
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部